downplay need mega deal
light sever product return growth
revenu non-gaap ep came forecast latter
benefit one-tim mileston adjust combin made
follow model chang although impact sale ep forecast
neglig rais eliqui estim base recent perform
ad tafamidi ttr stabil model conserv peak risk-adjust sale
pend data lower out-year steril inject sale pfizer
reiter sale ep guidanc mid-point compar
updat forecast respect chang
po base blend valuat dcf wacc termin
growth rate price-to-earnings maintain buy rate due key growth
brand differenti enjoy first-mov advantag diversifi us major
takeaway call
focu result consum strateg review option still tabl
given accept offer thu far manag still expect make decis
could includ full partial separ keep busi
 capit alloc prioriti remain unchang dividend buyback
reinvest make sens manag
emphas intern pipelin invest deni need transform
deal exist one appropri valuat tafamidi transthyretin
ttr cardiomyopathi discuss pipelin asset question base
around potenti label commerci opportun work advanc
regulatori discuss continu view drug potenti blockbust
follow posit data mortal cv hospit outstand question
remain around magnitud benefit data yet present broad label incl
polyneuropathi competit dynam fda action expect alnylam
ioni drug around mid-year howev believ co pivot
studi data wild-typ hereditari ttr combin manag believ
could repres cardiomyopathi patient diagnos
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
exhibit result guidanc
market sale administr non-gaap
billion
billion
billion
billion
billion
million incom million incom
price object po base blend averag dcf forward price-to-earnings po
impli stock trade ep current
multipl consensu ep multipl base
regress analysi histor us major pharma forward month price-to-earnings multipl
year forward compound-annual-growth-rate ep believ dcf analysi base reason
assumpt includ modest sale growth compound-annual-growth-rate
respect reflect loss exclus lyrica viagra collect
account us sale forecast near-term headwind
off-set key growth brand xeljanz ibranc xtandi flat
sale growth follow downward rebas us sale pipelin
overal sale forecast out-year sale dcf
assum wacc tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi in-lin forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
